FDA adds NAION eye warning to labels of all GLP-1 receptor agonists
The US FDA is requiring a Warnings and Precautions entry on non-arteritic anterior ischemic optic neuropathy for all GLP-1 RAs, citing a potential increased risk of this rare eye condition.

At a glance
- FDA concluded there is a potential increased risk of rare NAION with GLP-1 RAs and is requiring a label warning for the whole class.
- In FDA's meta-analysis of 126 trials, NAION occurred at 6.4 per 100,000 person-years with GLP-1 RAs and 3.8 per 100,000 person-years with comparators.
- Doctors should ask patients to report sudden painless vision loss in one eye at once and refer promptly to an ophthalmologist if NAION is suspected.
The study
This is a drug safety communication from the US FDA, published on 2026-11-09. It is a regulatory announcement, not a new trial. FDA is requiring all application holders of GLP-1 receptor agonist (GLP-1 RA) medicines to add information on non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of labelling. NAION is rare. It can cause sudden, painless loss of vision in one eye, including permanent vision loss.
FDA began its review after a July 2024 paper by Hathaway et al. on semaglutide. FDA noted several limitations of that paper but judged that further assessment was needed. It then reviewed clinical trial data, animal data and postmarketing data, including observational studies and case reports.
What they found
FDA's meta-analysis covered 126 trials with 134,253 patients (78,217 on GLP-1 RAs and 56,036 on a comparator). Total exposure was 288,879 person-years (PY). The comparator was placebo or a non-GLP-1 RA glucose-lowering medicine. There were 15 probable NAION events: 10 with GLP-1 RAs, 5 with placebo and none with other glucose-lowering medicines. The incidence was 6.4 per 100,000 PY with GLP-1 RAs and 3.8 per 100,000 PY with comparators.
FDA also ran a retrospective cohort study in its Sentinel network. It included adults with type 2 diabetes who started a GLP-1 RA, an SGLT-2 inhibitor or a DPP-4 inhibitor between 2019 and 2024. Incidence ranged from 26 to 32 per 100,000 PY. Compared with SGLT-2 inhibitors, the hazard ratio for GLP-1 RAs was 1.19 (95% CI 0.91 to 1.54), which was not statistically significant. Compared with DPP-4 inhibitors, the hazard ratio was 1.43 (95% CI 1.02 to 2.01), an increased risk.
FDA says methodologically rigorous published observational studies consistently reported increased risk against DPP-4 and SGLT-2 inhibitors. NAION cases have been reported for all currently marketed GLP-1 RA products. Adverse event reports were hard to interpret because NAION risk factors overlap with conditions common in people given these drugs.
How much weight to give it
FDA calls the risk "potential", and that wording matters. The trial meta-analysis pooled many trials but found only 15 events. The source gives no confidence interval for the 6.4 and 3.8 rates. The cohort data are observational, so they show association and not cause. The result against SGLT-2 inhibitors was not statistically significant, while the result against DPP-4 inhibitors was. FDA's review of the available animal data did not identify a mechanism by which GLP-1 RAs could increase NAION risk. NAION is rare, and the source gives a general-population incidence of 2.3 to 10.2 per 100,000 persons per year in adults older than 50. Still, FDA considered the combined evidence enough to require a class-wide label change. The source does not say who funded the individual studies.
For your clinic
Read the updated labelling and the full FDA communication before changing practice. Some general points follow from it.
- FDA advises health care professionals to instruct patients to report sudden, painless vision loss, visual field deficits or other visual disturbances in one eye straight away.
- FDA advises prompt referral to an ophthalmologist if NAION is suspected.
- FDA advises considering stopping the GLP-1 RA in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk. FDA says patients who have had a NAION event should talk with their health care professional about whether to continue or stop the GLP-1 RA.
- Patients with a history of NAION are at increased risk of recurrence. If NAION has occurred in one eye, the other eye is also at increased risk.
- FDA lists smoking, diabetes, high blood pressure, sleep apnoea, anaemia and kidney disease as possible risk factors for NAION.
The source does not report any action by Indian regulators. Check Indian labelling and professional guidance for updates.
Source
FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition
US FDA drug news. US FDA drug news. 9 November 2026
Cite this report: Diabesity Rounds. FDA adds NAION eye warning to labels of all GLP-1 receptor agonists. 2026. doi:10.5281/zenodo.24236963
Teaching a session? Download this report as a slide (PNG, free to use with credit).
For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.
More on glp-1 and incretin drugs
- CagriSema 1.7 mg and 1.0 mg each cut bodyweight more than placebo in REDEFINE 9Randomised trial · 16 November 2026
- CHMP backs two insulin aspart biosimilars and issues tirzepatide contraceptive adviceRegulatory · 14 November 2026
- Pemvidutide in MASH: non-invasive liver markers improve at 48 weeksRandomised trial · 13 November 2026
- Trevogrumab reduced lean mass loss on semaglutide in phase 2 trialRandomised trial · 13 November 2026
Go deeper
- CASPIAN Certificate in Obesity MedicineRegister interest for the next batch
- Beta Cell AcademyCME for doctors in Hyderabad
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.
Or follow on WhatsApp or Telegram (every report, as it is published), watch on YouTube, listen on Spotify or Apple Podcasts, or follow on LinkedIn. Not sure? Pick one.